A systematic review on the possible role of microRNA-155 in cancer treatment.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Overexpression of microRNA-155 (miR-155) has been associated with cancer development, metastasis, and possible drug resistance. This systematic review analyzed the evidence from the existing literature on miR-155 expression in cancer patients undergoing treatment. METHODS: A thorough literature search was conducted in databases and search engines (ProQuest, PubMed, and Google Scholar) from January 2019 to December 2024 to identify clinical evidence on miR-155 expression in cancer treatments. To assess miR-155 expression in relation to clinical outcomes, we included 15 cancers in this systematic review. Following the PRISMA 2020 guidelines, three independent reviewers selected, extracted, and assessed the data against the predefined inclusion criteria, and a fourth reviewer verified the assessments and resolved discrepancies. RESULTS: Of the 15 cancers analyzed, 19 eligible studies covering eight cancers were identified and included in the review, namely breast cancer, non-small cell lung cancer, pediatric acute lymphoblastic leukemia, cutaneous melanoma, non-muscle-invasive bladder cancer, papillary thyroid cancer, pancreatic ductal adenocarcinoma, and diffuse large B-cell lymphoma. Screening and evaluation of these 19 studies showed that miR-155 expression varied by cancer type, treatment strategy, and patient sample type. While most studies associated miR-155 overexpression with treatment resistance, a few reported an association between elevated miR-155 expression and enhanced treatment sensitivity. A limitation of this study is that the search for studies reporting miR-155 expression in relation to therapeutic outcomes in patients with cancer was restricted to three databases and a 5-year timeframe. CONCLUSION: Overall, the results of this study indicate that the prognostic and predictive significance of miR-155 warrants further evaluation. SYSTEMATIC REVIEW REGISTRATION: PROSPERO ID, CRD42025632573.